anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present application discloses a secretory protein, including polypeptide sequence, nucleic acid sequence, operating principle and application area of sDSS1 protein. The sDSS1 protein is a secretory protein of higher primate, and can be detected in human serum and CSF. The sDSS1 protein can be combined with oxidation protein under nonenzymatic condition to form polymer or with A² polypeptide to reduce formation of A² oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidation protein, A² oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly. The protein can be used to prevent and treat the diseases induced by oxidation protein, glycated protein, A² protein accumulation, amylin protein accumulation or excessive formation or accumulation of other pathogenic proteins with similar features, and has important potential in biological medicine.
The Patient Identification Form, Modified Borg Scale, Vital Signs Record Chart, and Blood Test Results Record Chart will be completed when the patient is first admitted to the ward. Music therapy intervention will be administered between 6:00 AM and 12:00 PM. Before the music therapy session, the patient will lie on their back at a 30-45 degree angle and rest for 5 minutes. The Modified Borg Scale and Vital Signs Record Chart will be completed just before the music therapy session begins. During the session, the patient will receive the music therapy intervention through headphones for 30 minutes. At the end of the 30-minute music session, the Modified Borg Scale and Vital Signs Record Chart will be completed again. Thirty minutes after the end of the music therapy intervention, the Modified Borg Scale and Vital Signs Record Chart will be completed once more.
PURPOSE:To obtain a composition for beautifying cosmetic, having safety and high effects. CONSTITUTION:A beautifying cosmetic composition comprising at least one of an extract of Auricularia auricula-juade Quel. of the family Auriculariaceae, an extract of Wasabia japonica Matsum. of the family Cruciferae and an extract of Fogopyrum esculentum Moench of the family Polygonaceae as an active ingredient. The extract extremely inhibits melanism without showing cytotoxicity. Consequently, the beautifying cosmetic composition comprising at least one of these extracts and their purified substances has safety and high beautifying effects.
Self-administered treatment with 10 sessions will be provided through care manuals in PDF format within the same web platform. Participants in this group will receive a manual within the platform with the same content of the sessions as the experimental group but in PDF format.
The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent inflammation and oxidative stress, which ultimately leads to progressive restriction of airflow. Extensive research findings have cogently suggested that the dysregulation of essential transition metal ions, notably iron, copper, and zinc, stands as a critical nexus in the perpetuation of inflammatory processes and oxidative damage within the lungs of COPD patients. Unraveling the intricate interplay between metal homeostasis, oxidative stress, and inflammatory signaling is of paramount importance in unraveling the intricacies of COPD pathogenesis. This comprehensive review aims to examine the current literature on the sources, regulation, and mechanisms by which metal dyshomeostasis contributes to COPD progression. We specifically focus on iron, copper, and zinc, given their well-characterized roles in orchestrating cytokine production, immune cell function, antioxidant depletion, and matrix remodeling. Despite the limited number of clinical trials investigating metal modulation in COPD, the advent of emerging methodologies tailored to monitor metal fluxes and gauge responses to chelation and supplementation hold great promise in unlocking the potential of metal-based interventions. We conclude that targeted restoration of metal homeostasis represents a promising frontier for ameliorating pathological processes driving COPD progression.
Ultra-sensitive detection of cancer by algorithmic analysis. In various embodiments, a sample comprising a plurality of polynucleotides is analyzed. A plurality of sequences of the plurality of polynucleotides is received. The plurality of sequences is provided to a trained classifier. The trained classifier is adapted to accept a plurality of sequences and output a class label indicative of the presence of a somatic variant within the plurality of sequences. A class label is received from the trained classifier indicative of the presence of a somatic clone within the plurality of sequences.
All participants are in the treatment arm. Patients with Esophagogastric Junction Outflow Obstruction (EGJOO) will undergo steroid treatment for 14 days. On the last day of the 14 day treatment, patient will undergo esophageal manometry testing to assess for treatment response. They will also be asked to complete follow-up Eckardt and BEDQ surveys.
The invention discloses a production method of a blushred isodon herb tea wine. The wine is prepared from the raw materials of, by weight: 8-15 parts of blushred isodon herb tea, 40-80 parts of distillate spirit, 8-16 parts of syrup, 2-6 parts of bee pollen, 5-10 parts of foldleaf daylily root, 2-3 parts of pseudostellaria hetero phyllaphylla, 5-10 parts of medlar, 2-4 parts of blueberry leaf, 1-2 parts of fennel, 2-3 parts of Mexican frangipani flower, 1-2 parts of paniculate microcos leaf, 1-2 parts of obtuseleaf senna seed, 1-2 parts of honeysuckle flower, 1-2 parts of boat-fruited sterculia seed, and proper amount of water. According to the invention, wine is combined with the blushred isodon herb tea. The tea wine is clear and transparent, and has a light tea fragrance and a mellow wine fragrance. Also, traditional Chinese medicine components such as foldleaf daylily root, paniculate microcos leaf, and obtuseleaf senna seed are added, such that a health-care function is added. The tea wine has the functions of invigorating stomach, regenerating body fluid, improving eyesight, tranquilizing, invigorating brain, resisting aging, sterilizing, and detoxifying. The tea wine has the advantages of simple preparation process, wide raw material, low cost, good taste, and suitability for people of all ages. When the tea wine is taken for a long time with proper amounts, body disease resistance can be enhanced.
A randomized controlled trial is proposed that will employ well-validated instruments and state-of-the-art techniques to assess improvements in cognitive functioning, functional status, mood, hippocampal neurogenesis and functional connectivity as well as anti-inflammatory and antioxidant effects of treatment with resveratrol. Design: The proposed study will be an intent-to-treat outpatient, randomized, double-blind, clinical trial of 93 Veterans who meet the Centers for Disease Control and Prevention and Kansas case definitions for GWI.

The study involves a comparison of resveratrol at a dose of 2000 mg and placebo. All doses will be administered orally once or twice daily. Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment. Morning dosing will be taken with or before breakfast. Evening dosing will be taken with or before dinner.
A network for mediating the peer-to-peer transfer of digital patient medical data includes a plurality of distributed agents each associated with a health care provider and connected to a central system. Periodically the agents collect local information relating to patient medical files and/or data streams, for example diagnostic images and associated reports, and process that information into metadata files acting as pointers to the original files. The metadata files are transmitted to the central system where they are parsed and the attributes are stored on the central system in patient records with records from the same patient grouped together whenever possible. Registered users can search the central system, even in the absence of a unique identifier, to identify patient records pointing to the remote patient medical files. Upon finding a patient medical file, the invention provides a streamlined process for communicating access authorization from the patient to the hospital or facility storing the medical files. Once patient authorization is received, secure processes are provided for transferring the data in its entirety to or for viewing by the user in a peer-to-peer fashion.
This is a study of patients with chronic pain to assess usability of a VR device at home. The main goals are 1) to collect data on feasibility of recruitment, 2) to collect data on daily adherence to therapy, and 3) to collect preliminary effectiveness data on pain and mood outcomes. There will be 7 sessions over one week, with each session lasting about 2-16 minutes. All patients recruited will be in the active arm; this is not a randomized pilot study.
Diet quality in childhood and adolescence can affect health outcomes such as physical and cognitive growth and preventing chronic diseases in adulthood. This study aimed to evaluate the relationship between diet quality using the modified youth healthy eating index (MYHEI) with socioeconomic factors and nutrition status in 7-12-year-old children in Iran. This descriptive-cross-sectional study was performed on 580 students in Zabol, Iran, selected through multistage cluster sampling. The diet was assessed through the 168-item food frequency questionnaire (FFQ) and eating behaviors. Then, the MYHEI scoring system was used to calculate the diet quality. In addition, we used the WHO growth indices, such as weight to age, height to age, and body mass index (BMI) to age ratios, to evaluate nutrition status. The mean total MYHEI score in children was 56.3 ± 11.2. Among children with the highest MYHEI score quartile, the number of girls was significantly higher than boys (p = 0.001). The prevalence of underweight, stunting, and wasting was 25.3%, 17.4%, and 21.7%, respectively. The prevalence of underweight (OR: 2.2; 95% CI  1.26, 3.90, p = 0.001) and stunting (OR: 3.2; 95% CI   1.65, 6.14, p = 0.006) were significantly lower in the higher MYHEI score quartile compared to the lower quartile. The overall diet quality of most children should be modified. Therefore, to improve the children's health and nutrition status, it is necessary to perform nutritional interventions such as training and promotional programs, especially in schools.
The invention belongs to polysaccharide with immunological activity, in particular to a franchet groundcherry fruit stem polysaccharide with immunological activity and a preparation method thereof. The method comprises the following steps of: extracting through a water immersion method; precipitating water immersion liquor extract; deproteinizing by using an enzyme method in combination with a Sevage method; drying to obtain rough polysaccharide; eluting with physiological saline; freeze-drying to obtain polysaccharide Q-WSP; and further purifying through HPLC (High Performance Liquid Chromatography) to obtain WSP (Water Soluble Polysaccharide). The molecular weight of the WSP obtained by using the method is about 7,000Da through HPLC measurement and the components are uniform. Monosaccharide components obtained through gas chromatographic analysis are Rha, Ara, Gal, Glc and GalA. The franchet groundcherry fruit stem polysaccharide has an immunological enhancement effect and can be used for foods and health-care products for improving the immunologic function of the organism. The preparation method is simple and reliable. The franchet groundcherry fruit stem has a wide source and is changed into things of value through development and utilization of the franchet groundcherry fruit stem polysaccharide.
Four randomized, controlled clinical trials were performed comparing 5 days versus 10 days of cefuroxime axetil tablets for the treatment of subjects with secondary bacterial infections of acute bronchitis. These trials enrolled a total of 1,253 subjects (Study 1 n = 360; Study 2 n = 177; Study 3 n = 362; Study 4 n = 354). The protocols for Study 1 and Study 2 were identical and compared cefuroxime axetil tablets 250 mg twice daily for 5 days, cefuroxime axetil tablets 250 mg twice daily for 10 days, and AUGMENTIN® (amoxicillin/clavulanate potassium) 500 mg 3 times daily for 10 days. These 2 trials were conducted simultaneously. Study 3 and Study 4 compared cefuroxime axetil tablets 250 mg twice daily for 5 days, cefuroxime axetil tablets 250 mg twice daily for 10 days, and CECLOR® (cefaclor) 250 mg 3 times daily for 10 days. They were otherwise identical to Study 1 and Study 2 and were conducted over the following 2 years. Subjects were required to have polymorphonuclear cells present on the Gram stain of their screening sputum specimen, but isolation of a bacterial pathogen from the sputum culture was not required for inclusion. Table 14 demonstrates the results of the clinical outcome analysis of the pooled trials Study 1/Study 2 and Study 3/Study 4, respectively. 

The response rates for subjects who were both clinically and bacteriologically evaluable were consistent with those reported for the clinically evaluable subjects.
Exforge HCT has not been studied in patients with heart failure.

Studies with amlodipine: In general, calcium channel blockers should be used with close monitoring, including close follow-up of fluid status, electrolytes, renal function, and blood pressure in patients with heart failure. Amlodipine (5-10 mg per day) has been studied in a placebo-controlled trial of 1,153 patients with NYHA Class III or IV heart failure on stable doses of ACE inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of about 14 months. There was no overall adverse effect on survival or cardiac morbidity (as defined by life-threatening arrhythmia, acute myocardial infarction, or hospitalization for worsened heart failure). Amlodipine has been compared to placebo in four 8-12 week studies of patients with NYHA class II/III heart failure, involving a total of 697 patients. In these studies, there was no evidence of worsened heart failure based on measures of exercise tolerance, NYHA classification, symptoms, or LVEF.

Studies with valsartan: Some patients with heart failure have developed increases in blood urea nitrogen, serum creatinine, and potassium on valsartan. These effects are usually minor and transient, and they are more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or valsartan may be required. In the Valsartan Heart Failure Trial, in which 93% of patients were on concomitant ACE inhibitors, treatment was discontinued for elevations in creatinine or potassium (total of 1.0% on valsartan vs. 0.2% on placebo). In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), discontinuation due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients and 0.8% of captopril-treated patients. Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function.
###  Myelosuppression

In clinical studies, myelosuppression was managed by dose interruption, dose reduction, or discontinuation of study therapy. Hematopoietic growth factor has been used in patients with resistant myelosuppression. Guidelines for dose modifications for adult and pediatric patients are summarized in Tables 3 and 4, respectively.

For pediatric patients with chronic phase CML, if Grade ≥ 3 neutropenia or thrombocytopenia recurs during complete hematologic response (CHR), interrupt Dasatinib tablets and resume at a reduced dose. Implement temporary dose reductions for intermediate degrees of cytopenia and disease response as needed.

For pediatric patients with Ph+ ALL, if neutropenia and/or thrombocytopenia result in a delay of the next block of treatment by more than 14 days, interrupt Dasatinib tablets and resume at the same dose level once the next block of treatment is started. If neutropenia and/or thrombocytopenia persist and the next block of treatment is delayed another 7 days, perform a bone marrow assessment to assess cellularity and percentage of blasts. If marrow cellularity is <10%, interrupt treatment with Dasatinib tablets until ANC >500/μL (0.5 x 109/L), at which time treatment may be resumed at full dose. If marrow cellularity is >10%, resumption of treatment with Dasatinib tablets may be considered.

###  Non-Hematologic Adverse Reactions

For adults with Ph+ CML and ALL, and pediatric patients with Ph+ CML, if a severe non-hematologic adverse reaction develops with Dasatinib tablet use, treatment must be withheld until the adverse reaction has resolved or improved. Thereafter, treatment can be resumed as appropriate at a reduced dose depending on the severity and recurrence [see Warnings and Precautions (5)].

For pediatric patients with Ph+ ALL, interrupt treatment for cases of grade ≥ 3 non-hematologic adverse reactions with the exception of liver function test abnormalities, and resume at a reduced dose when resolved to grade ≤1. For elevated direct bilirubin over 5 times the institutional upper limit of normal (ULN), interrupt treatment until improvement to baseline or grade ≤1. For elevated AST/ALT over 15 times the institutional ULN, interrupt treatment until improvement to baseline or grade <1\. For recurrent liver function test abnormalities as above, reduce the dose if this adverse reaction recurs after reinitiation of Dasatinib tablets. Dose reduction recommendations are described in Table 5.
The invention discloses a multifunctional medicine chest which comprises a box body and a cover body arranged on one side of the box body. A drawer is arranged in the box body. The multifunctional medicine chest further comprises a control device. The control device comprises a control unit, an input unit, a storage unit and a display unit. The input unit, the storage unit and the display unit are connected with the control unit. When a user stores medicine, the input unit acquires medicine information of medicine and transmits the medicine information to the control unit. The control unit judges the category of the medicine and the drawer where the medicine is required to be arranged, stores corresponding data to the storage unit and transmits the data to a display unit to display the data. When the user takes the medicine, the input unit acquires a part of medicine information input by the user and transmits the information to the control unit, the control unit searches for the medicine information, the category name and the drawer where the medicine is arranged according to the part of medicine information input by the user and transmits relevant data to the display unit to display the data.
Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
PROBLEM TO BE SOLVED: To obtain a stabilizer excellent in stickiness-fixing effect of denture and persistency of the fixed effect, having good usability, free from sense of incongruity and unpleasant taste when used and having excellent feeling to users by using a specific natural water-soluble polymer compound as a tacky agent. SOLUTION: This stabilizer for artificial tooth uses glucomannan. The glucomannan is a nonionic natural polymer extracted from bulb of a plant of the genus Amorphophalus and the component is a polysaccharide consisting mainly of D-mannose and D-glucose. A glucomannan extracted and purified in high purity by using ethanol as a solvent and having >=200,000 weight average molecular weight, especially preferably combination of a glucomannan having 200,000 to 800,000 weight average molecular weight and a glucomannan having 1,000,000 to 2,000,000 weight average molecular weight is preferably used as the glucomannan. Such glucomannan forms sol having extremely high viscosity in a state dissolved in water, especially at pH4-8 and the glucomannan is non- spinnable, pasteless and odorless and free from sense of incongruity when melted into mouth.  The compounding amount of glucomannan is about 5-100wt.%.
Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total. Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
Novel amine derivs. (I) and its pharmaceutically acceptable salts are prepd. by (i) reacting arylhydroxy compd. of formula ArOH with epichlorohydrin in the presence of solvent and base at reflux temp. to produce aryletherepoxide and (ii) reacting aryletherepoxide with amine of formula H2N-Y-COOR in the presence of alcohol or another suitable solvent at reflux temp..  In the formula, Y=C1-4 alkylene, phenylene, R=C1-2 alkyl or -CH2CF3, X=1 or 2, Ar=Ph or naphthyl.
Patients in the chemotherapy alone treatment arm who achieved at least stable disease during the Bridging Therapy Period while receiving nanoliposomal irinotecan (NLIR) + Fluorouracil/folinic acid (FU/FA) will continue treatment with the chemotherapy regimen they received during the Treatment Period. This regimen will be administered in 28-day cycles until the development of disease progression.
PROBLEM TO BE SOLVED: To obtain an excellent cosmetic composition safe to human skin, having surface active action, cleaning action, cell activating action, germicidal/ antimicrobial action, containing a very small amount of a specific metal colloid or further a small amount of clay. SOLUTION: This cosmetic composition comprises 0.01-5wt.%, preferably 0.1-3wt.%, more preferably 0.2-2wt.% of finely powdery gold colloid. The addition of the gold colloid to a cosmetic extremely raises effectiveness of the cosmetic and especially improved touch after human use. The reason is considered to be deeply related to the natural phenomena of the earth. The cosmetic composition comprises 0.01-5wt.% of the gold colloid and 0.5-10wt.% of clay. The gold used is preferably fine powdery gold having about 0.3-0.9μm, especially about 0.6μm particle diameter. The clay used is preferably ultrafine powder having <=1μm, preferably about 0.3μm particle diameter.